Skip to main content
Thursday, 22 October 2026
TaxClue News

Licences

Business licences, registrations and approvals.

11stories

Licences · 8 October 2026

Government approves cap on margins of non-scheduled anti-cancer drugs at 30% of MRP; NPPA to notify after DGHS expert committee finalises the list

The Government has approved a cap on the margins charged in the supply and sale of non-scheduled anti-cancer drugs, limiting them to 30% of the Maximum Retail Price, according to a Department of Pharmaceuticals release of 8 October 2026. An expert committee under the Directorate General of Health Services will finalise the list of medicines, after which NPPA will take a decision and issue the notification. Manufacturers of these drugs will be required to maintain their current production levels.

Licences · ReliefMargin cap: 30% of MRPMargin cap on non-scheduled anti-cancer drugsFrom February 2019, trade margins capped by NPPA on 42 selected non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013.NowA wider cap approved: margins limited to 30% of MRP on non-scheduled anti-cancer medicines across categories, with the list to be finalised by a DGHS expert committee and notified by NPPA.
ReliefSource: PIB release, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, 8 October 2026Read the full story →

October 2026

September 2026

August 2026

The morning brief

One email each working morning with the day’s tax, GST and company-law news. It is starting soon; leave your address and it comes to you from day one.